Chenyang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chenyang Li has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Haiqiang Wu
School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, China
5 shared publications - Xun Song
College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China
4 shared publications - Zhendan He
School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China
4 shared publications Bin-Fa Liang
School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China
3 shared publications- Dahong Yao
College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China
3 shared publications - Liang He
Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, Guangzhou 510642, China
3 shared publications
Latest Publications
- 20 January 2026
- Published by Elsevier in Leukemia Research
- Vol. 165, 108167
Discovery of METTL3 inhibitor C191-0266 as a leukemia therapeutic through targeted modulation of protective autophagy
- 20 January 2026
- Published by Elsevier in Leukemia Research
- Vol. 165, 108167
Discovery of METTL3 inhibitor C191-0266 as a leukemia therapeutic through targeted modulation of protective autophagy
- 31 January 2025
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 12 (6) , 2294-2302
Photoactivation of the cGAS-STING pathway and pyroptosis by an endoplasmic reticulum-targeting ruthenium( ii ) complex for cancer immunotherapy
Three multifunctional ruthenium(II) complexes (Ru1–Ru3) modified with cholic acid were synthesized, which exhibited excellent singlet oxygen-generating ability and near-infrared (NIR) aggregation-induced emission (AIE) phosphorescence activity. Cellular toxicity assays revealed that Ru1 displayed pronounced phototoxicity against both human breast cancer cells (MDA-MB-231) and murine breast cancer cells (4T1), achieving a maximum phototoxicity index (PI) of 83.3. Mechanistic studies indicated that Ru1 exhibited superior targeting affinity for the endoplasmic reticulum (ER). Upon irradiation at 450 nm, it stimulated the production of reactive oxygen species (ROS) and initiated ER stress. This stress activated the interferon gene stimulator (STING) pathway's signaling cascade within the ER, prompting a Golgi apparatus response. The consequent activation induced pyroptosis and sequentially engaged the downstream proteins p-TBK1 and p-IRF3 within the STING pathway, thus promoting the secretion of antitumor cytokines and the elicitation of tumor immune responses. In vivo experiments conducted on Balb/c mice have demonstrated significant anti-tumor immune effects exhibited by Ru1. In summary, the immune modulation and targeted intervention by metal complexes represent an innovative and promising therapeutic strategy for cancer. This approach is anticipated to yield new perspectives for the development of metal complexes that augment tumor immunotherapy.
- 31 January 2025
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 12 (6) , 2294-2302
Photoactivation of the cGAS-STING pathway and pyroptosis by an endoplasmic reticulum-targeting ruthenium( ii ) complex for cancer immunotherapy
Three multifunctional ruthenium(II) complexes (Ru1–Ru3) modified with cholic acid were synthesized, which exhibited excellent singlet oxygen-generating ability and near-infrared (NIR) aggregation-induced emission (AIE) phosphorescence activity. Cellular toxicity assays revealed that Ru1 displayed pronounced phototoxicity against both human breast cancer cells (MDA-MB-231) and murine breast cancer cells (4T1), achieving a maximum phototoxicity index (PI) of 83.3. Mechanistic studies indicated that Ru1 exhibited superior targeting affinity for the endoplasmic reticulum (ER). Upon irradiation at 450 nm, it stimulated the production of reactive oxygen species (ROS) and initiated ER stress. This stress activated the interferon gene stimulator (STING) pathway's signaling cascade within the ER, prompting a Golgi apparatus response. The consequent activation induced pyroptosis and sequentially engaged the downstream proteins p-TBK1 and p-IRF3 within the STING pathway, thus promoting the secretion of antitumor cytokines and the elicitation of tumor immune responses. In vivo experiments conducted on Balb/c mice have demonstrated significant anti-tumor immune effects exhibited by Ru1. In summary, the immune modulation and targeted intervention by metal complexes represent an innovative and promising therapeutic strategy for cancer. This approach is anticipated to yield new perspectives for the development of metal complexes that augment tumor immunotherapy.
- 11 December 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 118, 118040
Design, synthesis and biological evaluation of new SIRT3 activators for the treatment of triple-negative breast cancer
- 11 December 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 118, 118040
Design, synthesis and biological evaluation of new SIRT3 activators for the treatment of triple-negative breast cancer
- 29 November 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 377, 606-618
A ROS-responsive hydrogel that targets inflamed mucosa to relieve ulcerative colitis by reversing intestinal mucosal barrier loss
- 29 November 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 377, 606-618
A ROS-responsive hydrogel that targets inflamed mucosa to relieve ulcerative colitis by reversing intestinal mucosal barrier loss
- 26 August 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 112, 117896
Design, synthesis and biological evaluation of a novel PAK1 degrader for the treatment of triple negative breast cancer
- 26 August 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 112, 117896
Design, synthesis and biological evaluation of a novel PAK1 degrader for the treatment of triple negative breast cancer
- 11 August 2024
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 260, 112695
Endoplasmic reticulum-targeted iridium(III) photosensitizer induces pyroptosis for augmented tumor immunotherapy
- 11 August 2024
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 260, 112695
Endoplasmic reticulum-targeted iridium(III) photosensitizer induces pyroptosis for augmented tumor immunotherapy
- Open Access
Isolation and Identification of Chemical Compounds from Agaricus blazei Murrill and Their In Vitro Antifungal Activities
This study explores the antifungal properties of Agaricus blazei Murrill, a valuable medicinal and edible fungus. Six compounds (1–6) were first isolated from A. blazei using various isolation techniques and identified using spectroscopic methods. These compounds include linoleic acid, 1,1′-oxybis(2,4-di-tert-butylbenzene), glycerol monolinoleate, volemolide (17R)-17-methylincisterol, (24s)-ergosta-7-en-3-ol, and dibutyl phthalate. This study also assesses the antifungal activities of these compounds against Trichophyton mentagrophology, Trichophyton rubrum, Candida albicans, and Cryptococcus neoformans. The results demonstrate varied sensitivities against these pathogenic fungi, with compound 2 showing significant inhibition against T. mentagrophology, compound 3 showing significant inhibition against T. rubrum, and compound 6 showing significant inhibition against C. albicans. This study underscores the medicinal potential of A. blazei as an antifungal agent and sheds light on its valuable research implications.
Open AccessIsolation and Identification of Chemical Compounds from Agaricus blazei Murrill and Their In Vitro Antifungal Activities
This study explores the antifungal properties of Agaricus blazei Murrill, a valuable medicinal and edible fungus. Six compounds (1–6) were first isolated from A. blazei using various isolation techniques and identified using spectroscopic methods. These compounds include linoleic acid, 1,1′-oxybis(2,4-di-tert-butylbenzene), glycerol monolinoleate, volemolide (17R)-17-methylincisterol, (24s)-ergosta-7-en-3-ol, and dibutyl phthalate. This study also assesses the antifungal activities of these compounds against Trichophyton mentagrophology, Trichophyton rubrum, Candida albicans, and Cryptococcus neoformans. The results demonstrate varied sensitivities against these pathogenic fungi, with compound 2 showing significant inhibition against T. mentagrophology, compound 3 showing significant inhibition against T. rubrum, and compound 6 showing significant inhibition against C. albicans. This study underscores the medicinal potential of A. blazei as an antifungal agent and sheds light on its valuable research implications.
- Open Access
Cytotoxic Compounds from Belamcanda chinensis (L.) DC Induced Apoptosis in Triple-Negative Breast Cancer Cells
Four compounds (1, 5, 7, and 8) were first isolated from the genus Belamcanda Adans. nom. conserv., and six known compounds (2–4, 6, 9, and 10) were isolated from the rhizome of Belamcanda chinensis (L.) DC. Their structures were confirmed by spectroscopic data. Herein, compounds 1–10 were rhapontigenin, trans-resveratrol, 5,7,4′-trihydroxy-6,3′,5′-trimethoxy-isoflavone, irisflorentin, 6-hydroxybiochannin A, iridin S, pinoresinol, 31-norsysloartanol, isoiridogermanal, and iristectorene B, respectively. All compounds were evaluated for their antiproliferative effects against five tumor cell lines (BT549, 4T1, MCF7, MDA-MB-231, and MDA-MB-468). Among them, compound 9 (an iridal-type triterpenoid) showed the highest activity against 4T1 and MDA-MB-468 cells. Further studies displayed that compound 9 inhibited cell metastasis, induced cells cycle arrest in the G1 phase, exhibited significant mitochondrial damage in 4T1 and MDA-MB-468 cells including excess reactive oxygen species, decreased mitochondrial membrane potential, and induced 4T1 and MDA-MB-468 cell apoptosis for the first time. In summary, these findings demonstrate that compound 9 exerts promising potential for triple-negative breast cancer treatment and deserves further evaluation.
Open AccessCytotoxic Compounds from Belamcanda chinensis (L.) DC Induced Apoptosis in Triple-Negative Breast Cancer Cells
Four compounds (1, 5, 7, and 8) were first isolated from the genus Belamcanda Adans. nom. conserv., and six known compounds (2–4, 6, 9, and 10) were isolated from the rhizome of Belamcanda chinensis (L.) DC. Their structures were confirmed by spectroscopic data. Herein, compounds 1–10 were rhapontigenin, trans-resveratrol, 5,7,4′-trihydroxy-6,3′,5′-trimethoxy-isoflavone, irisflorentin, 6-hydroxybiochannin A, iridin S, pinoresinol, 31-norsysloartanol, isoiridogermanal, and iristectorene B, respectively. All compounds were evaluated for their antiproliferative effects against five tumor cell lines (BT549, 4T1, MCF7, MDA-MB-231, and MDA-MB-468). Among them, compound 9 (an iridal-type triterpenoid) showed the highest activity against 4T1 and MDA-MB-468 cells. Further studies displayed that compound 9 inhibited cell metastasis, induced cells cycle arrest in the G1 phase, exhibited significant mitochondrial damage in 4T1 and MDA-MB-468 cells including excess reactive oxygen species, decreased mitochondrial membrane potential, and induced 4T1 and MDA-MB-468 cell apoptosis for the first time. In summary, these findings demonstrate that compound 9 exerts promising potential for triple-negative breast cancer treatment and deserves further evaluation.
- 2 January 2023
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 52 (5) , 1291-1300
Near-infrared AIE-active phosphorescent iridium(iii) complex for mitochondria-targeted photodynamic therapy
A near-infrared Ir(iii) complex with aggregation-induced emission (AIE) properties exhibits potent photodynamic anticancer activity in vitro and in vivo upon 525 nm light irradiation.
- 2 January 2023
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 52 (5) , 1291-1300
Near-infrared AIE-active phosphorescent iridium(iii) complex for mitochondria-targeted photodynamic therapy
A near-infrared Ir(iii) complex with aggregation-induced emission (AIE) properties exhibits potent photodynamic anticancer activity in vitro and in vivo upon 525 nm light irradiation.